Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. more
Time Frame | PSTV | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.55% | -0.94% | -2.6% |
1-Month Return | -13.01% | -5.08% | -1.08% |
3-Month Return | -32.7% | -10.62% | 3.45% |
6-Month Return | -33.13% | -6.18% | 8.57% |
1-Year Return | -43.68% | 1.98% | 24.3% |
3-Year Return | -93.95% | -0.93% | 25.58% |
5-Year Return | -97.09% | 33.84% | 84.07% |
10-Year Return | -100% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 7.00M | 303.00K | - | 224.00K | 4.91M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":4.33,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":3.2,"profit":true},{"date":"2023-12-31","value":70.21,"profit":true}] |
Cost of Revenue | 5.37M | 2.70M | 66.00K | 712.00K | 9.69M | [{"date":"2019-12-31","value":55.37,"profit":true},{"date":"2020-12-31","value":27.86,"profit":true},{"date":"2021-12-31","value":0.68,"profit":true},{"date":"2022-12-31","value":7.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 1.63M | (2.40M) | (66.00K) | (488.00K) | (4.78M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-146.79,"profit":false},{"date":"2021-12-31","value":-4.04,"profit":false},{"date":"2022-12-31","value":-29.88,"profit":false},{"date":"2023-12-31","value":-292.53,"profit":false}] |
Gross Margin | 23.34% | (791.09%) | (Infinity%) | (217.86%) | (97.23%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-3390.11,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":-933.6,"profit":false},{"date":"2023-12-31","value":-416.67,"profit":false}] |
Operating Expenses | 10.65M | 9.89M | 12.43M | 19.94M | 8.54M | [{"date":"2019-12-31","value":53.45,"profit":true},{"date":"2020-12-31","value":49.59,"profit":true},{"date":"2021-12-31","value":62.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.86,"profit":true}] |
Operating Income | (3.66M) | (9.58M) | (12.49M) | (19.71M) | (13.32M) | [{"date":"2019-12-31","value":-365700000,"profit":false},{"date":"2020-12-31","value":-958400000,"profit":false},{"date":"2021-12-31","value":-1249200000,"profit":false},{"date":"2022-12-31","value":-1971200000,"profit":false},{"date":"2023-12-31","value":-1332100000,"profit":false}] |
Total Non-Operating Income/Expense | (1.43M) | 286.00K | (1.82M) | (1.13M) | 10.00K | [{"date":"2019-12-31","value":-498.6,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-636.36,"profit":false},{"date":"2022-12-31","value":-394.06,"profit":false},{"date":"2023-12-31","value":3.5,"profit":true}] |
Pre-Tax Income | (3.28M) | (8.24M) | (13.40M) | (20.27M) | (13.32M) | [{"date":"2019-12-31","value":-328300000,"profit":false},{"date":"2020-12-31","value":-824100000,"profit":false},{"date":"2021-12-31","value":-1339900000,"profit":false},{"date":"2022-12-31","value":-2027500000,"profit":false},{"date":"2023-12-31","value":-1331600000,"profit":false}] |
Income Taxes | 9.46M | 1.11M | 932.00K | 563.00K | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":11.7,"profit":true},{"date":"2021-12-31","value":9.85,"profit":true},{"date":"2022-12-31","value":5.95,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (12.74M) | (9.35M) | (14.33M) | (20.84M) | - | [{"date":"2019-12-31","value":-1274200000,"profit":false},{"date":"2020-12-31","value":-934800000,"profit":false},{"date":"2021-12-31","value":-1433100000,"profit":false},{"date":"2022-12-31","value":-2083800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (3.28M) | (8.24M) | (13.40M) | (20.27M) | (13.32M) | [{"date":"2019-12-31","value":-328300000,"profit":false},{"date":"2020-12-31","value":-824100000,"profit":false},{"date":"2021-12-31","value":-1339900000,"profit":false},{"date":"2022-12-31","value":-2027500000,"profit":false},{"date":"2023-12-31","value":-1331600000,"profit":false}] |
Income From Discontinued Operations | (7.60M) | - | - | - | - | [{"date":"2019-12-31","value":-760400000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (12.74M) | (9.35M) | (14.33M) | (20.84M) | (13.32M) | [{"date":"2019-12-31","value":-1274200000,"profit":false},{"date":"2020-12-31","value":-934800000,"profit":false},{"date":"2021-12-31","value":-1433100000,"profit":false},{"date":"2022-12-31","value":-2083800000,"profit":false},{"date":"2023-12-31","value":-1331600000,"profit":false}] |
EPS (Diluted) | (13.92) | (1.60) | (1.13) | (0.84) | (2.57) | [{"date":"2019-12-31","value":-1392,"profit":false},{"date":"2020-12-31","value":-160,"profit":false},{"date":"2021-12-31","value":-113,"profit":false},{"date":"2022-12-31","value":-84,"profit":false},{"date":"2023-12-31","value":-257,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PSTV | |
---|---|
Cash Ratio | 0.40 |
Current Ratio | 0.44 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PSTV | |
---|---|
ROA (LTM) | -69.39% |
ROE (LTM) | -522.50% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PSTV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.74 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PSTV | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.15 |
P/B | 3.76 |
Price/FCF | NM |
EV/R | 18.19 |
EV/Ebitda | NM |
Plus Therapeutics Inc (PSTV) share price today is $1.07
Yes, Indians can buy shares of Plus Therapeutics Inc (PSTV) on Vested. To buy Plus Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PSTV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Plus Therapeutics Inc (PSTV) via the Vested app. You can start investing in Plus Therapeutics Inc (PSTV) with a minimum investment of $1.
You can invest in shares of Plus Therapeutics Inc (PSTV) via Vested in three simple steps:
The 52-week high price of Plus Therapeutics Inc (PSTV) is $2.67. The 52-week low price of Plus Therapeutics Inc (PSTV) is $0.93.
The price-to-earnings (P/E) ratio of Plus Therapeutics Inc (PSTV) is
The price-to-book (P/B) ratio of Plus Therapeutics Inc (PSTV) is 3.76
The dividend yield of Plus Therapeutics Inc (PSTV) is 0.00%
The market capitalization of Plus Therapeutics Inc (PSTV) is $6.43M
The stock symbol (or ticker) of Plus Therapeutics Inc is PSTV